Please assess the completion status of the following clinical trial:

Trial Title: A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of acute myeloid leukemia (AML) according to the World Health Organization (WHO) classification~* Diagnosis of AML which has relapsed or is refractory to standard of care and no curative therapy exists~* Karnofsky or Lansky score of at least 50~* Must be recovered from acute toxicity of any prior treatment~* Must have adequate organ function according to protocol-defined criteria~* Agrees to protocol-defined use of effective contraception~* Female participants of childbearing potential must have a negative serum or urine pregnancy test at Day 1 of Cycle 1~Exclusion Criteria:~* Prior treatment with decitabine or azacitidine~* Acute promyelocytic leukemia (M3 subtype in the French-American-British \[FAB\] classification system)~* CNS3 disease~* acute myeloid leukemia (AML) associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes~* White blood cell count greater than 40x10\^9 cells/liter(L)~* Known allergies, hypersensitivity, or intolerance to decitabine or cytarabine or their excipients~* Contraindications to the use of cytarabine per local prescribing information or prior adverse reactions to cytarabine which would prevent further use~* Currently enrolled in the treatment phase of an interventional investigational study~* Female who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of study drug (however, the period after which it becomes safe to become pregnant after the last dose of treatment is not known)~* Male who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug~* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments~* Any social or medical condition that in the investigator's opinion renders the participant unfit for study participation~* History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease~* History of human immunodeficiency virus (HIV) antibody positive

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Decitabine and cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).